The deletion of SMAD4, often observed in advanced tumour stages and lymph node involvement, is typically accompanied by decreased peritumoral lymphocyte aggregation and a lower presence of tumor‐infiltrating lymphocytes (TILs). Here, SMAD4 is linked to neoplasm.